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Abstract: Levodopa has been the gold standard therapy for the motor symptoms of Parkinson’s 
disease for more than three decades. Although it remains the most effective treatment, its long-term 
use is associated with motor ﬂ  uctuations and dyskinesias that can be disabling for patients and dif-
ﬁ  cult for physicians to manage medically. In the last 10 years, the catechol-O-methyltransferase 
(COMT) inhibitor tolcapone has been studied for its efﬁ  cacy as an adjunctive treatment to levodopa 
plus a dopa decarboxylase inhibitor. Adjunctive therapy with tolcapone can signiﬁ  cantly reduce 
the dose of levodopa required. Moreover, treatment with tolcapone signiﬁ  cantly reduces wearing 
off and on-off periods in ﬂ  uctuating patients and improves ‘on’ time in patients with stable disease. 
Tolcapone has assumed a new place in the arsenal of medications for Parkinson’s disease. This paper 
reviews the pharmacology, safety and efﬁ  cacy of tolcapone in patients with advanced Parkinson’s 
disease. After some initial concerns about its safety, tolcapone has been shown to be safe if used 
and monitored according to guidelines regarding liver function. Tolcapone produces expected 
dopaminergic side effects, including headache, nausea, insomnia, as well as diarrhea; however, 
these side effects are generally mild and as a rule do not result in discontinuation of therapy.
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Introduction
Levodopa has remained the gold standard treatment for the characteristic motor 
symptoms of Parkinson’s disease (PD) for over 30 years.1 When administered with 
a dopamine decarboxylase inhibitor (DDCI), levodopa is still the most effective 
treatment for the cardinal motor symptoms of PD.2 Its effects are quick and it is well 
tolerated in the short to medium term.3 However, the long-term use of levodopa is 
limited by treatment-emergent motor ﬂ  uctuations and dyskinesias that can be both 
challenging to manage and a signiﬁ  cant source of disability for patients. The motor 
complications of levodopa are relatively common, occurring in about 10% of patients 
per year of treatment, so that by 5 years approximately 50% and by 10 years nearly 
100% of patients have developed them.4 Concerns over the possibility of levodopa-
induced motor complications are especially relevant for younger patients with longer 
life expectancies.
The management of dyskinesias and motor ﬂ  uctuations in PD patients treated with 
levodopa is challenging, but a number of guidelines and approaches are available. 
There is increasing evidence that dopamine agonists may be given in lieu of levodopa 
to manage motor symptoms of Parkinson’s disease and to reduce complications.5 This 
approach would delay the need for levodopa and provide more continuous dopamine 
stimulation and therefore also delay the emergence of motor complications. For 
motor ﬂ  uctuations speciﬁ  cally, options include increasing the dose of levodopa, using 
controlled release levodopa, adjunctive therapy with a dopamine agonist, or using Clinical Interventions in Aging 2009:4 110
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subcutaneous apormorphine for rescue.5 In other cases it 
may be appropriate to add other adjunctive medications in 
an attempt to directly or indirectly offset motor ﬂ  uctuations 
and/or to reduce the dose of levodopa required for symptom 
control.
Levodopa crosses the blood–brain barrier after oral 
administration, where it is decarboxylated by aromatic acid 
decarboxylase in the brain and periphery to produce dopa-
mine. Levodopa is typically administered with a DDCI to 
reduce peripheral metabolism, reducing peripheral dopami-
nergic side effects (eg, postural hypotension, nausea), and 
increasing the amount of levodopa reaching the brain. When 
given in this way, 5% to 10% of levodopa reaches the brain. 
When decarboxylation is blocked, levodopa is metabolized 
predominantly to 3-O-methyldopa (3-OMD) by catechol-
O-methyltransferase (COMT), a selective and ubiquitous 
enzyme involved in the catabolism of levodopa.6 In the brain, 
COMT metabolizes levodopa to 3-OMD and dopamine to 
homovanillic acid.7 In the periphery, COMT is involved in 
the conversion of levodopa to 3-OMD. Based on this mecha-
nism, it was posited that inhibiting COMT would result in 
less degradation of levodopa, and that, when administered 
with a DDCI, would increase levodopa bioavailability, CNS 
delivery, and continuity of dopamine stimulation. As a result 
the dose of levodopa required for therapeutic efﬁ  cacy could 
be reduced, and this lower exposure to levodopa should delay 
or prevent motor complications.
Tolcapone is a potent, selective and reversible inhibitor 
of COMT in the periphery.8 It also exerts COMT inhibition 
in the brain, but the relevance of this effect to its efﬁ  cacy in 
PD is less clear.9 Treatment with tolcapone has been shown 
to widen the therapeutic window for levodopa as expected, 
by reducing the doses needed for symptom control.
This review will provide an overview of  the pharmacology 
of tolcapone as it relates to both efﬁ  cacy and safety, and will 
then describe literature from clinical trials on the efﬁ  cacy 
of tolcapone as adjunctive therapy in ﬂ  uctuating and stable 
patients with PD.
Pharmacology
Tolcapone is typically administered in oral daily doses of 
100 mg or 200 mg tid. The pharmacokinetics of the 100 mg 
and 200 mg doses show similar pharmacokinetics alone or in 
combination with levodopa plus a DDCI.10–12 In studies with 
healthy volunteers tolcapone shows linear pharmacokinetics 
over the 50 to 400 mg dose range.13 The pharmacokinetics of 
tolcapone are the same in healthy volunteers as in patients 
with PD.14
After oral administration tolcapone is rapidly absorbed, 
with 60% bioavailability due to ﬁ  rst pass metabolism.15 It 
reaches peak plasma concentration in 30 minutes to 2 hours. 
Tolcapone is highly plasma protein bound (more than 99.9%) 
and thus has restricted distribution.13 Tolcapone undergoes 
extensive metabolism, primarily through glucuronidation to 
inactive 3-O-β,D-glucuronic acid conjugate, with 0.5% of 
drug excreted unchanged.13,16
Tolcapone is eliminated fairly quickly, with an elimination 
half-life of 1.6 to 3.4 hours.17 The area under the tolcapone 
plasma-concentration time curve is dose-dependent,10 and its 
pharmacokinetics do not vary in the presence of food, after 
single vs repeated doses, or as a function of age.18 There is 
no evidence of pharmacodynamic tolerance after repeated 
dosing.19 There is little accumulation of the methylated metabo-
lite of tolcapone after long-term administration.
Tolcapone reversibly decreases S-COMT activity in 
erythrocytes in a dose-dependent manner, with a rapid time 
to maximum inhibition of less than 2 hours. After oral doses 
of 100 mg or 200 mg, maximum COMT inhibition is 72% 
and 80%, respectively and returns to baseline approximately 
18 hours after the 200 mg dose.10,11 COMT inhibition with 
tolcapone leads to dose-dependent increases in the plasma 
half-life of levodopa as well as its area under the curve 
(AUC),10,11 without impacting Cmax or Tmax. Factor et al20 
showed that administration of tolcapone led to an 80% 
increase in the half-life of levodopa. Other studies have 
shown that tolcapone in doses of 100 or 200 mg increase the 
bioavailability of levodopa by as much as 2.1 fold in both 
healthy volunteers and patients with Parkinson’s disease.21 
Consequently, levodopa levels are more continuous (less 
fluctuating), which should reduce the development of 
dyskinesias.22,23 Indeed, clinical trials in PD have conﬁ  rmed 
that tolcapone tid enhances the beneﬁ  t of levodopa.8
In addition, tolcapone has been shown to lower the elevated 
homocysteine levels associated with levodopa/DDCI treatment 
in patients with Parkinson’s disease,24 which may have the 
added beneﬁ  t of reducing long-term degenerative changes and 
dementia associated with hyperhomocysteinemia.
The safety and tolerability of tolcapone have been the 
subject of much discussion and debate since its initial arrival 
on the market in 1997/1998 based on elevated liver transmi-
nases and hepatotoxicity in a small number of initial patients25 
and during post-marketing studies.26 A number of authors 
have pointed out that these patients were not managed per 
protocol and that some were continued on tolcapone in spite 
of liver function tests that dictated otherwise.27 Nevertheless, 
these f  indings led to the withdrawal of tolcapone in Europe Clinical Interventions in Aging 2009:4 111
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and in Canada, and a black box warning in the US. The 
warning required that physicians only use tolcapone after 
considering or trying other medications, that patients pro-
vide informed consent prior to being treated, and that liver 
enzymes be monitored according to a rigorous schedule. 
Importantly, the warning mandated that tolcapone therapy 
be terminated if liver enzymes exceeded the upper limits of 
normal even once during the treatment period. In the ensu-
ing 7 years and 40,000 more patient years of tolcapone use, 
no additional occurrences of fatal hepatotoxicity have been 
linked to the treatment. In light of this, a reconsideration of 
tolcapone led to its reintroduction into Europe and a re-evalu-
ation of monitoring guidelines by FDA.
Indeed, more recent data have suggested that tolcapone 
may have a wider safety window than previously believed.26 
For example, a review of tolcapone global safety conducted 
by Valeant Pharmaceuticals International (data on ﬁ  le) 
showed that severe hepatocellular damage occurred in only 
0.04% of patients over the past 7 years; most of those showing 
signs of liver toxicity showed elevated liver transaminases 
but no clinical signs or symptoms.
A review by Olanow28 of 1535 patients with PD showed 
that half of the patients that continued on tolcapone showed 
normalization of ALT/AST within 1 to 3 months as com-
pared to 2 to 3 weeks for those who discontinued the drug. 
These ﬁ  ndings suggest that nonresponders may be identiﬁ  ed 
early in the course of any liver abnormalities, and can be 
switched to a different medication as indicated. In another 
study, 677 patients who had never received levodopa were 
randomly assigned to either placebo add-on therapy or 
tolcapone add-on therapy to standard doses of levodopa.29 
Liver function elevations at the upper limit of normal (ULN) 
occurred in 20.2% and 27.5% of patients in the placebo and 
active treatment groups, respectively; increases greater than 
3 times the ULN occurred in 1.2 and 1.7% of patients. No 
serious hepatoxicity was recorded.
The mechanism of tolcapone-induced hepatoxicity is 
not known but may relate to abnormalities in mitochondrial 
respiration in hepatocytes due to uncoupling of oxidative 
phosphorylation.30 Tolcapone-induced hepatotoxicity could 
also be related to elevated catecholamine levels in patients 
receiving other drugs with adrenergic receptor-mediated 
toxicity.31
Current recommendations suggest performing liver 
function tests before starting tolcapone, and avoiding its use 
in patients with evidence of liver disease or who have had 
two aminotransferease levels above the ULN. Aminotrans-
ferase should be monitored every 2 weeks during ﬁ  rst year 
of treatment, every 4 weeks for the next 6 months and then 
every 8 weeks thereafter.32,13
Tolcapone may also produce dopaminergic side effects 
related to the increased availability of levodopa, including 
most notably dyskinesia but also nausea, dizziness, orthostatic 
hypotension, vomiting, anorexia, sleep disorders, somnolence 
and hallucinations. These side effects can usually be reduced 
by reducing the dose of levodopa.3 Tolcapone can also cause 
signiﬁ  cant diarrhea, headache, abdominal pain and urine 
discoloration.33,34
Use as adjunctive therapy
Tolcapone is indicated for patients with idiopathic, ﬂ  uctuating 
PD who are being treated with levodopa plus a DDCI,13 but the 
speciﬁ  cs differ in the United States and elsewhere. In the United 
States, tolcapone is speciﬁ  cally indicated for patients who are 
not responding to or are not candidates for other adjunctive 
treatment. In Europe, tolcapone is indicated for patients who 
are either not responding to the other COMT inhibitor or who 
are intolerant to this type of medication.32 Treatment should be 
discontinued in patients who fail to show substantial beneﬁ  t 
within the ﬁ  rst 3 weeks of treatment.13,32 Although tolcapone 
also is efﬁ  cacious in patients with stable PD, this class of drug 
is not recommended for stable patients. In addition, tolcapone 
is not meant to be used in early untreated patients not taking 
levodopa/DDCI.17 Although tolcapone has been shown to 
inhibit central COMT, its clinical efﬁ  cacy seems to be mainly 
mediated through inhibition of peripheral COMT and depends 
on concomitant use of exogenous levodopa.17
The efﬁ  cacy of oral tolcapone as adjunctive therapy has been 
shown in several studies over a period of 3 weeks to 3 months 
in both stable patients and those with motor ﬂ  uctuations.26 
Tolcapone has been shown to signiﬁ  cantly reduce ‘off’ time 
in Parkinson’s patients with motor ﬂ  uctuations20,34–38 and to 
increase motor function in Parkinson’s patients with and without 
ﬂ  uctuations.39,26
In a more recent, multicenter, randomized, placebo-
controlled parallel group study by Lees and colleages,29 inves-
tigators sought to evaluate the safety and efﬁ  cacy of adjunctive 
therapy with tolcapone (100 mg tid; n = 355) vs placebo 
(n = 342) in patients with early Parkinson’s disease treated 
with levodopa. Patients were assessed for efﬁ  cacy (UPDRS) 
monthly for 6 months and then every 3 months, and for safety 
(liver function tests) at weeks 2, 3, 6, 9, and 12 months. The 
mean total dose of levodopa over the course of the study was 
higher in the placebo group (306 mg) than the tolcapone group 
(284). Although the authors found changes in liver enzymes as 
shown in previous studies, these changes were transient even Clinical Interventions in Aging 2009:4 112
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when the tolcapone was continued; a large number of patients 
had slightly high transaminases at baseline but did not go on 
to develop hepatotoxicity. Another recent study has shown that 
6 months of treatment with 200 mg tolcapone plus levodopa/
DDCI plus selegiline can promote signiﬁ  cant improvement in 
memory and attention in patients with advanced PD.40
Studies also have been done to directly compare tolcapone 
to another COMT inhibitor on the market, entacapone, or 
to explore the impact of switching from one of these agents 
to another. In one study comparing tolcapone (n = 14) to 
entacapone (n = 11) in PD patients with motor ﬂ  uctuations, tol-
capone was associated with greater reduction in UPDRS motor 
score and complication subscores (−5.07 vs 2.46, p  0.02), 
duration of ‘off’ periods (1 hour vs 0.27 hour p  0.03), and 
levodopa dose requirement (−400 mg vs 179.2, p  0.04).20
Another study (N = 40)41 in severe PD looked at the 
effects of switching from entacapone to tolcapone. During 
tolcapone treatment, ‘on’ time increased by 15% whereas dur-
ing entacapone treatment it increased by 8%; similarly, ‘off’ 
time was reduced by 16% and 7% in the tolcapone and enta-
capone groups, respectively. Tolcapone was associated with 
signiﬁ  cantly greater reduction of levodopa dose compared 
to entacapone (p = 0.05) and was also superior with respect 
to ‘wearing off ’ severity and relevant clinical improvement 
(70%–73% for tolcapone vs 56% for entacapone).29
In a double-blind study by Pahwa and colleagues, patients 
treated with entacapaone were randomly assigned to continue 
treatment with entacapone (n = 75) or to switch to tolcapone 
(n = 75). As in the Lees et al study29 ‘on’ time increased by 
more than 1 hour per day in 43% of patients treated with 
entacapone and 53% of those treated with tolcapone, and by 
more than 3 hours per day in 13% and 25% of those groups, 
respectively. Whereas 39% of patients on tolcapone showed 
moderate to marked improvement, only 25% of patients on 
entacapone showed an improvement of this magnitude.
In the SWITCH study, motor function was assessed in 
patients who had switched from entacapone to tolcapone; 
those that switched had at least 3 hours of additional ‘on’time 
(p = 0.018) and had clinically, but not statistically, signiﬁ  -
cant moderate or marked improvement on the Investigator 
Global Assessment. More of the tolcapone responders had 
long-term beneﬁ  ts compared to entacapone. In stable patients, 
tolcapone showed an overall global improvement of 77% after 
4 weeks.26
Conclusion
Based on what is known about the neurobiology underlying 
PD, the pharmacology responsible for both the beneﬁ  cial 
and unwanted effects of levodopa, and its clariﬁ  ed safety 
proﬁ  le, tolcapone appears to be a rational adjunctive therapy 
for patients treated with levodopa who do not respond to 
entacapone. Tolcapone may have a role in PD patients with 
motor ﬂ  uctuations despite treatment with entacapone and/or 
monoamine oxidase B.
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